Investors will be keeping a close eye on Pfizer's earnings when they report first quarter results on May 5th. Pfizer has been heavily focused on the M&A business with its bid to buy British drug maker AstraZeneca. On Friday, Pfizer increased its bid for the company from $10 billion to $14 billion. Analysts expect the pharmaceutical company to earn $0.55 a share on $12.07 billion in revenue. If Pfizer meets Wall Street forecasts, it would represent a decline in sales growth of 10.6 percent from a year ago.